Stryker Corporation $SYK Shares Purchased by Raiffeisen Bank International AG

Raiffeisen Bank International AG boosted its position in Stryker Corporation (NYSE:SYK) by 15.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 101,593 shares of the medical technology company’s stock after acquiring an additional 13,313 shares during the quarter. Raiffeisen Bank International AG’s holdings in Stryker were worth $35,976,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Stryker by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the period. Geode Capital Management LLC increased its stake in shares of Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares in the last quarter. Norges Bank purchased a new position in shares of Stryker during the 4th quarter worth approximately $1,822,272,000. Finally, Legal & General Group Plc grew its stake in Stryker by 2.7% in the 4th quarter. Legal & General Group Plc now owns 2,366,107 shares of the medical technology company’s stock worth $831,616,000 after acquiring an additional 62,817 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $305.82 on Friday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $117.24 billion, a price-to-earnings ratio of 35.40, a PEG ratio of 1.95 and a beta of 0.78. The firm’s fifty day simple moving average is $316.75 and its 200 day simple moving average is $344.20. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the firm earned $2.84 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio is 40.74%.

Analyst Ratings Changes

Several analysts have commented on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. BTIG Research decreased their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. UBS Group decreased their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Finally, William Blair reiterated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.